On 1st April, G1 Therapeutics, Inc. (referred to as "G1") developed the world’s first innovative drug of its kind aimed at improving the effectiveness of chemotherapy treatment for cancer patients and improving their quality of life. The first batch of locally produced products in Haikou were officially launched. At the same time, this drug is also the first product of the "Lecheng Research + Haikou Production" model.

"Kesela" is the first international innovative drug in Hainan to be launched through the policy of Lecheng Pilot Zone, and it is also the first achievement under the "Lecheng Research and Application + Haikou Production" enclave economy model.

It only took 14 months for "Kesela" to go public in the United States and obtain domestic import registration approval. Simcere Pharmaceutical submitted a real estate application in the form of a supplementary application on 13th January, 2023. On 20th December, 2023, the transfer of real estate production was approved, and the first batch of real estate products were launched on 1st April, 2024. The commercial production of "Kesela" in Haikou High tech Zone will greatly reduce the production cost of this variety and benefit more patients.